Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Back to Search
Print
Bookmark Trial

NCT00141232

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Irvine, Ayrshire, KA12 OAY, United Kingdom
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to entry.

- Are not known to have had a cardiovascular event

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- They are taking prescribed lipid lowering therapy


- Have triglycerides > or = 8.0 mmol/L

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Type 2 DiabetesEvaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00141232
  1. Irvine, Ayrshire
  2. Farnworth, Bolton
  3. Thornhill, Cardiff
  4. Fowey, Cornwall
  5. Launceston, Cornwall
  6. Penzance, Cornwall
  7. Penzance, Cornwall
  8. Saltash, Cornwall
  9. St Austell, Cornwall
  10. Darlington, County Durham
  11. Newton Aycliffe, County Durham
  12. Three Bridges, Crawley
  13. Plymouth, Devon
  14. Plymouth, Devon
  15. Bexhill on Sea, East Sussex
  16. Bexhill-On-Sea, East Sussex
  17. Bath, England
  18. Dronfield, Sheffield, England
  19. Surrey, England
  20. Halstead, Essex
  21. Stonehouse, Gloucestershire
  22. Southampton, Hampshire
  23. Hildenborough, Kent
  24. Thorneton-Clevely, Lancashire
  25. Balham, London
  26. Fulham, London
  27. Tooting, London
  28. Hayes, Middlesex
  29. Wellingborough, Northamptonshire
  30. Cookstown, Northern Ireland
  31. Frome, Somerset
  32. Fetcham, Surrey
  33. Woking, Surrey
  34. Crawley, West Sussex
  35. Leeds, West Yorkshire
  36. Bradford-on-Avon, Wiltshire
  37. Melksham, Wiltshire
  38. Swindon, Wiltshire
  39. Trowbridge, Wiltshire
  40. Warminster, Wiltshire
  41. Sheffield, Yorkshire
  42. Bath,
  43. Bath,
  44. Belfast,
  45. Birmingham,
  46. Bucks,
  47. Chesterfield,
  48. Chippenham, Wiltshire,
  49. Cornwall,
  50. County Antrim, Northern Ireland,
  51. Darlington,
  52. Dundee,
  53. Dundee,
  54. East Sussex,
  55. Isle of Wight,
  56. Isle of Wight,
  57. London,
  58. London,
  59. Westbury,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Type 2 DiabetesStudy Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
NCT01336738
  1. Jonesboro, Arkansas
  2. Jonesboro, Arkansas
  3. Los Angeles, California
  4. Palm Springs, California
  5. Jacksonville, Florida
  6. Melbourne, Florida
  7. West Palm Beach, Florida
  8. Conyers, Georgia
  9. Chicago, Illinois
  10. Louisville, Kentucky
  11. Fall River, Massachusetts
  12. Brooklyn, New York
  13. Cary, North Carolina
  14. Wilmington, North Carolina
  15. Columbus, Ohio
  16. East Providence, Rhode Island
  17. East Providence, Rhode Island
  18. Mount Pleasant, South Carolina
  19. Bristol, Tennessee
  20. Kingsport, Tennessee
  21. Dallas, Texas
  22. Houston, Texas
  23. Houston, Texas
  24. Houston, Texas
  25. San Antonio, Texas
  26. Charlottesville, Virginia
  27. Kenosha, Wisconsin
  28. Milwaukee, Wisconsin
  29. Winnipeg, Manitoba
  30. Strathroy, Ontario
  31. Thornhill, Ontario
  32. Toronto, Ontario
  33. Laval, Quebec
  34. St-Romuald, Quebec
  35. Budapest,
  36. Seoul,
  37. Seoul,
  38. Seoul,
  39. Guadalajara, Jalisco
  40. Guadalajara, Jalisco
  41. Monterrey, Nuevo Leon
  42. Bratislava,
  43. Tainan,
  44. Taipei,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Official Title  ICMJE A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Brief Summary

The AFORRD trial is asking three important questions:

What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given with or without a statin? Are there simple techniques that can help people to take their tablets on a regular basis?

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Diabetes, Type 2
Intervention  ICMJE Drug: Atorvastatin and Omega-3 fatty acids
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 21, 2008)		810
Original Enrollment  ICMJE
 (submitted: August 30, 2005)		1000
Actual Study Completion Date  ICMJE July 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • They have a diagnosis of Type 2 Diabetes Mellitus for at least 3 months prior to entry.
  • Are not known to have had a cardiovascular event

Exclusion Criteria:

  • They are taking prescribed lipid lowering therapy
  • Have triglycerides > or = 8.0 mmol/L
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00141232
Other Study ID Numbers  ICMJE A2581114
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Churchill Hospital
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP